Alvotech (OISE:ALVO) Change In Receivables : kr-3,283 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Alvotech Change In Receivables?

Alvotech's change in receivables for the quarter that ended in Mar. 2024 was kr780 Mil. It means Alvotech's Accounts Receivable declined by kr780 Mil from Dec. 2023 to Mar. 2024 .

Alvotech's change in receivables for the fiscal year that ended in Dec. 2023 was kr-3,534 Mil. It means Alvotech's Accounts Receivable increased by kr3,534 Mil from Dec. 2022 to Dec. 2023 .

Alvotech's Accounts Receivable for the quarter that ended in Mar. 2024 was kr5,670 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Alvotech's Days Sales Outstanding for the three months ended in Mar. 2024 was 102.14.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Alvotech's liquidation value for the three months ended in Mar. 2024 was kr-216,841 Mil.

Alvotech Change In Receivables Historical Data

The historical data trend for Alvotech's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alvotech Change In Receivables Chart

Alvotech Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-6,185.82

1,388.80

-1,859.29

-1,758.54

-3,534.26

Alvotech Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial									528.77	1,928.84	-662.79	-5,329.09	779.89

Alvotech Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-3,283 Mil.

Alvotech (OISE:ALVO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Alvotech's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	5670.101	/	5065.32	*	91
=	102.14

2. In Ben Graham's calculation of liquidation value, Alvotech's accounts receivable are only considered to be worth 75% of book value:

Alvotech's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8908.294	-	236340.632	+	0.75 * 5670.101	+	0.5 * 12677.869
=	-216,841

Alvotech Change In Receivables Related Terms

Thank you for viewing the detailed overview of Alvotech's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Alvotech (OISE:ALVO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alvotech (OISE:ALVO) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ALVO:USA Z45:Germany

Address

9, rue de Bitbourg, Luxembourg, LUX, L-1273

Website

https://www.alvotech.com

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.